Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-22
2005-02-22
Naff, David M. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S450000, C435S176000, C435S178000, C435S179000, C435S180000, C435S325000, C435S366000, C530S300000, C530S329000, C530S331000, C530S811000, C530S813000, C530S814000, C530S815000
Reexamination Certificate
active
06858582
ABSTRACT:
Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.
REFERENCES:
patent: 4780455 (1988-10-01), Liberman
patent: 4793986 (1988-12-01), Serino
patent: 4847240 (1989-07-01), Ryser
patent: 5017566 (1991-05-01), Bodor
patent: 5023252 (1991-06-01), Hseih
patent: 5024998 (1991-06-01), Bodor
patent: 5039794 (1991-08-01), Wier
patent: 5053394 (1991-10-01), Ellestad
patent: 5112863 (1992-05-01), Hashimoto
patent: 5124146 (1992-06-01), Neuwelt
patent: 5149794 (1992-09-01), Yatvin
patent: 5153179 (1992-10-01), Eibl
patent: 5177064 (1993-01-01), Bodor
patent: 5254342 (1993-10-01), Shen
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5258453 (1993-11-01), Kopecek
patent: 5270312 (1993-12-01), Glase
patent: 5284876 (1994-02-01), Shashoua
patent: 5389623 (1995-02-01), Bodor
patent: 5405834 (1995-04-01), Bundgaard
patent: 5413996 (1995-05-01), Bodor
patent: 5434137 (1995-07-01), Black
patent: 5442043 (1995-08-01), Fukuta
patent: 5466683 (1995-11-01), Sterling
patent: 5525727 (1996-06-01), Bodor
patent: 5543389 (1996-08-01), Yatvin
patent: 5543390 (1996-08-01), Yatvin
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5840674 (1998-11-01), Yatvin et al.
patent: 6063759 (2000-05-01), Yatvin et al.
patent: 6339060 (2002-01-01), Yatvin et al.
patent: 077529 (1983-04-01), None
patent: 109484 (1983-04-01), None
patent: 301223 (1983-12-01), None
patent: 203676 (1986-12-01), None
patent: 279887 (1988-08-01), None
patent: 350287 (1990-01-01), None
patent: WO 8502342 (1985-06-01), None
patent: WO 8900166 (1989-11-01), None
patent: WO 8910348 (1989-11-01), None
patent: WO 8911299 (1989-11-01), None
patent: WO 8902909 (1990-01-01), None
patent: WO 9000555 (1990-01-01), None
patent: WO 9001002 (1990-09-01), None
patent: WO 9010448 (1990-09-01), None
patent: WO 9004087 (1991-02-01), None
patent: WO 9101750 (1991-02-01), None
patent: WO 9104014 (1991-04-01), None
patent: WO 9104745 (1991-04-01), None
patent: WO 9102691 (1991-10-01), None
patent: WO 9114438 (1991-10-01), None
patent: WO 9116024 (1991-10-01), None
patent: WO 9116024 (1991-10-01), None
patent: WO 9119726 (1991-12-01), None
patent: WO 9401131 (1994-01-01), None
patent: WO9401138 (1994-01-01), None
patent: WO 9402178 (1994-02-01), None
patent: WO 9403424 (1994-02-01), None
patent: WO 9403434 (1994-02-01), None
patent: WO 9406450 (1994-03-01), None
patent: WO 9425616 (1994-11-01), None
patent: WO 9507092 (1995-03-01), None
patent: WO 9522963 (1995-08-01), None
patent: WO 9532002 (1995-11-01), None
patent: WO 9600537 (1996-01-01), None
patent: WO 9604001 (1996-02-01), None
patent: WO 9622303 (1996-07-01), None
Abbas et al., “Antigen Presentation and T Cell Antigen Recognition,”Cellular as J. Mol. Immunol.(W.B. Saunders Co.; Philadelphia), pp. 116-136.
Afzelius et al.,Biochim. Biophys. Acta979: 231-238 (1989).
Alvarez-Dominquez et al., “Role of Complement Component C1q in Phagocytosis ofListeria monocytogenesby Murine Macrophage-Like Cell Lines,”Infect. Immun.61:3664-3672, (1993).
Anderson et al.,J. Am. Chem. Soc.85: 3039 (1963).
Ashborn et al., “Anti-HIV Activity of CD4-Pseudomonas Exotoxin on Infected Primary Human Lympocytes and Monocyte/Macrophages,”J. Infect. Dis.163: 703-709 (1991).
Baer,Can. J. Biochem. Phys.34: 288-304 (1955).
Bai and Amidon, “Structural Specificity of Mucosal-Cell Transport and Metabolism of Peptide Drugs: Implications for Oral Peptide Drug Delivery,”Pharm. Res.9: 969-978 (1992).
Bai et al., “Utilization of Peptide Carrier System to Improve Intestinal Absorption: Targeting Prolidase as a Prodrug-Converting Enzyme,”J. Pharm. Sci.81: 113-116 (1992).
Barlow et al., “Mast cells and T lymphocytes in chronic urticaria,”Clinical&Experimental Allergy25: 317-322 (1995).
Baroni et al., “Expression of HIV in Lymph Node Cells of LAS Patients: Immunohistology, In Situ Hybridization, and Identification of Target Cells,”Am. J. Pathol.133: 498-506 (1988).
Berdel et al.,Lipids22: 943-946 (1987).
Bickel et al., “Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery,”Proc. Natl. Acad. Sci. USA90: 2618-2622 (1993).
Blakey, “Drug Targeting with Monoclonal Antibodies,”Acta Oncol.31: 91-97 (1992).
Blight et al., “Detection of hepatitis C virus RNA by in situ hybridization,”Liver12: 286-289 (1992).
Blum et al., “Bloood clearance and organ deposition of intravenously administered colloidal particles: the effects of particle size, nature and shape,”Int. J. Pharm.12: 135-146 (1982).
Boehnlein et al., “Characterization of Esterase and Alcohol Dehydrogenase Activity in Skin. Metabolism of Retinyl Palmitate to Retinol (Vitamin A) During Percutaneous Absorption,”Pharmaceutical Research11: 1155-1159 (1994).
Boman et al., “Cell-free immunity in Cecropia: A model system for antibacterial proteins,”Eur. J. Biochem.201: 23-31 (1990).
Borissova et al., “Biodegradable Microspheres. 17. Lysosomal Degradation of Primaquine-Peptide Spacer Arms,”Journal of Pharmaceutical Sciences,vol. 84, No. 2, Feb. 1995, pp. 256-262.
Bou-Gharios et al., “Expression of ectopeptidases in scleroderma,”Annals of Rheumatic Disease54: 111-116 (1995).
Brewster et al., “Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified β-Cyclodextrins,”J. Pharm. Sci.77: 981-985 (1985).
Bromberg et al., “Detection ofBorditella pertussisAssociated with the Alveolar Macrophages of Children with Human Immunodeficiency Virus Infection,”Infect. Immun.59: 4715-4719 (1991).
Brown & Silvius,Biochim. Biophys. Acta1023: 341-351 (1990).
Brown et al., “Induction of Cell Surface Peptidase Activity: A Global Response to Cell Stress Correlated with Apoptosis,”J. Cellular Biochemistry54: 320-331 (1994).
Brynestad et al.,J. Virol.64:680-685 (1990).
Buchmeier and Heffron, “Induction of Salmonella Stress Proteins upon Infection of Macrophages,”Science248: 730-732 (1990).
Büyüktimkin et al., “Synthesis and Enhancing Effect of Dodecyl 2-(N,N-Dimethylamino)propionate on the Transepidermal Delivery of Indomethacin, Clonidine, and Hydrocortisone,”Pharmaceutical Research10: 1632-1637 (1993).
Chang, “Leishmania donovani:Promastigote-Macrophage Surface Interactions in Vitro,”Exp. Parisitol.48:175-189 (1979).
Clarke et al., “Detection of HIV-1 in human lung macrophages using the polymerase chaine reaction,”AIDS4: 1133-1136 (1990).
Comiskey & Heath,Biochim. Biophys. Acta1024: 307-317 (1990).
Cordier et al., “In vivo Activation of Alveolar Macrophages in Ovine Lentivirus Infection,”Clin. Immunol. Immunopathol.55: 355-367 (1990).
Couveur and Puisieux, “Nano- and microparticles for the delivery of polypeptides and proteins,”Adv. Drug Deliv. Rev.10: 141-162 (1993).
Dachun et al., “Localization and Quantification of
Gallicchio Vincent S.
Meredith Michael J.
Stowell Michael HB
Yatvin Milton B.
McDonnell & Boehnen Hulbert & Berghoff
Naff David M.
Oregon Health and Sciences University
LandOfFree
Composition containing porous microparticle impregnated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition containing porous microparticle impregnated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition containing porous microparticle impregnated with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3455808